BIDMC's George Tsokos receives two prestigious awards at 2014 ACR Annual Scientific Meeting

George Tsokos, MD, Chief of Rheumatology at Beth Israel Deaconess Medical Center (BIDMC) and a national leader in the field of lupus research was honored by both the Lupus Foundation of America and the American College of Rheumatology (ACR) with two prestigious awards presented during the 2014 ACR Annual Scientific Meeting recently held in Boston.

Tsokos received the Evelyn V. Hess Research Award from the Lupus Foundation of America. The Hess Award honors an investigator whose work has significantly advanced the understanding of the causes and management of lupus. Lupus is an autoimmune disease that typically affects women between the ages of 15 and 45 and leads to inflammation and damage to various body tissues, including the joints, skin, kidneys, heart, lungs blood vessels and brain.

Tsokos was also the recipient of the Distinguished Basic Investigator Award from the American College of Rheumatology. An ACR Award of Distinction, the award is presented to a basic scientist who has made outstanding contributions to the field of rheumatology.

"For more than 20 years, George Tsokos has led investigations that have been instrumental in defining the molecular and biochemical abnormalities in T-cells of individuals with lupus," said BIDMC Chair of Medicine Mark Zeidel, MD. "This work has not only furthered our understanding of the disease's origins, but has led to the discovery of new therapeutic targets that are helping to improve the lives of patients with this debilitating disease."

Tsokos received his doctorate in medicine from the University of Athens, Greece, and trained in internal medicine at Georgetown University and in rheumatology at the National Institutes of Health (NIH). He was a member of the Uniformed Services at Walter Reed Hospital between 1987 and 2007, before joining BIDMC as Chief of Rheumatology in 2007. He also serves as BIDMC Center Director of a FOCIS Center of Excellence (Federation of Clinical Immunology Societies.)

SOURCE Beth Israel Deaconess Medical Center

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease